Medeon Biodesign (ROCO:6499) Cash And Cash Equivalents : NT$1,265.2 Mil (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Medeon Biodesign Cash And Cash Equivalents?

Medeon Biodesign's quarterly cash and cash equivalents declined from Jun. 2023 (NT$1,927.88 Mil) to Sep. 2023 (NT$1,471.30 Mil) but then stayed the same from Sep. 2023 (NT$1,471.30 Mil) to Mar. 2024 (NT$1,265.25 Mil).

Medeon Biodesign's annual cash and cash equivalents declined from Dec. 2020 (NT$1,128.13 Mil) to Dec. 2021 (NT$735.32 Mil) and declined from Dec. 2021 (NT$735.32 Mil) to Dec. 2022 (NT$483.90 Mil).

Medeon Biodesign Cash And Cash Equivalents Historical Data

The historical data trend for Medeon Biodesign's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medeon Biodesign Cash And Cash Equivalents Chart

Medeon Biodesign Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Cash And Cash Equivalents

Get a 7-Day Free Trial

328.11

472.06

1,128.13

735.32

483.90

Medeon Biodesign Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Mar24
Cash And Cash Equivalents	Get a 7-Day Free Trial															483.90	691.46	1,927.88	1,471.30	1,265.25

Medeon Biodesign Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Medeon Biodesign (ROCO:6499) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Medeon Biodesign Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Medeon Biodesign's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Medeon Biodesign (ROCO:6499) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Medeon Biodesign Inc (ROCO:6499) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 116, HouGang Street, 7th Floor, Shilin District, Taipei, TWN, 11170

Website

http://www.medeonbio.com

Medeon Biodesign Inc develops medical device products. The main services of the Group are the research and development of medical devices, manufacturing, and sale of injection molding and components of medical devices. The company provides products in the fields of cardiovascular and laparoscopic. Its business includes Medical Device Development Department and Medical Device Components Manufacturing and Sales Department. The majority of the company revenue comes from Medical Device Components Manufacturing and Sales Department segment. The company revenue is mainly derived from the USA.

Medeon Biodesign (ROCO:6499) Headlines

No Headlines